Pharma & Bio
Technology
Medical AI Driven by Lunit Inc.… Attention on VUNO, Inc.’s Valuation and NEUROPHET Inc.’s Big Pharma Deal [Bio Spotlight]
On the 26th, stock prices of medical artificial intelligence (AI) companies rose across the board in the domestic pharmaceutical, biotech, and healthcare sectors. Following Lunit Inc.’s announcement o…
- 2026-10-28 07:01:03
- NA EUN-KYUNG
Technology
Lunit’s Summit Deal Boosts Korean Medical AI Stocks [K-Bio Pulse]
South Korean medical artificial intelligence stocks rallied on October 26 after Lunit announced a research partnership with U.S. biotech company Summit Therapeutics to identify AI biomarkers for a nex…
- 2026-10-28 07:01:03
- NA EUN-KYUNG
Technology
Funding Shortage Persists Despite 100 Billion Won Capital Increase… Could Joint Ventures with Lenders Be the Breakthrough?
Qurient Co., Ltd.(115180)is set to secure funding for research and development over the next three years through a 105.8 billion won rights offering. With large-scale cash outflows from new drug devel…
- 2026-10-28 06:06:02
- KIM SAE-MI
Technology
G2GBIO Surges; Noul and FutureChem Hit Price Limits [K-Bio Pulse]
South Korean biotech stocks with company-specific catalysts rallied Friday even as the KOSDAQ pharmaceutical index fell for a second consecutive session.G2GBio jumped 20.6% on expectations that a drug…
- 2026-10-27 08:01:04
- NA EUN-KYUNG
Technology
G2GBIO, Inc. Soars on Expectations of Collaboration with Novo… Noul Co., Ltd. and FutureChem Co., Ltd. Hit Daily Price Limits [Bio Spotlight]
On the 23rd, as the KOSDAQ Pharmaceutical Index fell for the second consecutive day, buying interest surged for stocks with positive individual catalysts. G2GBIO, Inc. has been on an upward trend for …
- 2026-10-27 08:01:03
- NA EUN-KYUNG
Technology
Two-Track Approach to Regenerative Medicine: Licensing and Hospitals… K-Cell and Gene Therapies Headed to Japan
(Graphic: ChatGPT)
South Korean companies are taking divergent approaches to entering the Japanese cell and gene therapy (CGT) market. While some companies aim to launch finished therapeutic produ…
- 2026-10-27 08:01:02
- Minji Son
Technology
Osstem Implant on Track to Recover 170 Billion Won in Operating Profit This Year... Will Its Restructuring Efforts Pay Off?
Osstem Implant’s earnings recovery is becoming evident in profits before it does in sales. The industry is highly optimistic about the possibility of a rebound in Osstem Implant’s performance this yea…
- 2026-10-27 07:02:03
- Kim Seung-kwon
Technology
Peptron, Inc.’s Animal Half-Life: Competitors’ Is Longer; Evidence for Monthly Human Dosing Remains Unclear
On the 16th, Peptron, Inc. posted a notice on its website refuting the contents of an article by PharmDaily titled “ Peptron, Which Promised ‘Once a Month for Up to 3 Months’… Efficacy Tests in Patent…
- 2026-10-27 06:01:02
- KIM SAE-MI
Lifestyle
[ESMO 2026] Ok Chan-young, Director of the Ligacem Center: “LCB02A Expected to Be Effective Even in Patients with Low Claudin 18.2 Expression”
“LCB02A uses exatecan as its payload. Drugs in the exatecan class have a bystander effect that allows them to attack surrounding cancer cells, and this effect is expected to be further enhanced throug…
- 2026-10-26 11:22:02
- Kim Jinsoo
Technology
Jeong Hyun-woo, Head of DIO Corporation’s China Branch: “China’s Second VBP Round Presents an Opportunity for a Rebound… Expanding Focus on Public Hospitals”
Jeong Hyun-woo, head of DIO Corporation’s China subsidiary, explained the current status of the company’s China operations at a recent investor relations (IR) briefing held at COEX in Seoul. (Photo: R…
- 2026-10-26 07:21:03
- KIM SAE-MI
PHARM EDAILY
Shorts